首页> 外文期刊>The Veterinary Journal >Molecular characterisation of canine nonsteroidal anti-inflammatory drug-activated gene (NAG-1)
【24h】

Molecular characterisation of canine nonsteroidal anti-inflammatory drug-activated gene (NAG-1)

机译:犬非甾体抗炎药激活基因(NAG-1)的分子表征

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Nonsteroidal anti-inflammatory drug (NSAID)-activated gene (NAG-1), a divergent member of the transforming growth factor o superfamily, was previously identified as a gene induced by several anti-tumorigenic compounds, including NSAIDs and peroxisome proliferator-activated receptor d (PPARd) ligands in humans. In this study, canine NAG-1 was characterised from a canine genomic database. Gene induction by some NSAIDs and PPARd ligands was demonstrated in canine osteosarcoma cell lines. Phylogenetic analysis indicates that canine NAG-1 is more homologous with the corresponding mouse and rat genes than with human NAG-1. Expression of canine NAG-1 was increased by treatment with piroxicam and SC-560 (NSAIDs) and the PPARd ligand rosiglitazone. This study demonstrates that canine NAG-1 is up-regulated by some anti-tumorigenic compounds in osteosarcoma cell lines and may provide an important target of chemotherapy in canine cancer.
机译:非甾体抗炎药(NSAID)激活基因(NAG-1)是转化生长因子超家族的一个不同成员,以前被鉴定为由多种抗致瘤性化合物(包括NSAID和过氧化物酶体增殖物激活受体)诱导的基因。人体内的d(PPARd)配体。在这项研究中,从犬基因组数据库中鉴定了犬NAG-1。在犬骨肉瘤细胞系中证实了某些NSAID和PPARd配体的基因诱导。系统发育分析表明,犬NAG-1与相应的小鼠和大鼠基因比与人NAG-1同源性更高。用吡罗昔康和SC-560(NSAIDs)和PPARd配体罗格列酮治疗可提高犬NAG-1的表达。这项研究表明,犬NAG-1被骨肉瘤细胞系中的某些抗致瘤化合物上调,并可能为犬癌的化学治疗提供重要靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号